ANDA 76237, held by Barr. Fluoxetine Hydrochloride.
As of Nov 16, 2026, ANDA 76237 (Fluoxetine Hydrochloride), held by Barr, was first approved by FDA on Mar 24, 2010, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 24, 2010 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fluoxetine HydrochlorideEQ 90MG BASE · capsule, delayed rel pellets;oral | Fluoxetine Hydrochloride | Discontinued |
| Aug 18, 2023 | Supplement 9Labeling · Standard review | Approved | None posted |
| Oct 8, 2021 | Supplement 7Labeling · Standard review | Approved | None posted |
| Oct 8, 2021 | Supplement 6Labeling · Standard review | Approved | None posted |
| Feb 28, 2012 | Supplement 4Labeling | Approved | None posted |
| Feb 28, 2012 | Supplement 3Labeling | Approved | None posted |
| Mar 24, 2010 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters